A survivor biobank to find who will develop late effects before they do
Two people can have identical treatment and only one develops heart failure or a second cancer years later. Collecting blood and genetic data from survivors could reveal who is at risk and who can be reassured.
Genetic variants (for instance in anthracycline cardiotoxicity), clonal haematopoiesis, and circulating biomarkers may predict late effects, but studies are small and scattered. A prospective survivor biobank with baseline and serial samples linked to treatment exposures and long-term outcomes would allow discovery and validation of predictive markers, enabling risk-adapted surveillance and preventive therapy.
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- IdeaRisk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaA risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaBiomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaA survivorship research endowment funded by a levy on curative therapy prices
Shares Cardio-oncology, Survivorship and late effects are neglected.
- TermTrastuzumab cardiotoxicity
Shares Cardio-oncology, Survivorship and late effects are neglected.
- InstitutionMovember
Shares Survivorship and late effects are neglected, Germline (hereditary) testing.
- RoadmapPaths to cures: interception, eradication, control